The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen‐deprivation therapy

Several data suggest that neuroendocrine (NE) differentiation in prostate cancer is implicated in the development of resistance to androgen‐deprivation therapy (ADT). This study was undertaken to assess the prognostic role of tissue chromogranin A (CgA) expression in patients addressed to ADT as opposed to those who did not.

[1]  A. Partin,et al.  Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis , 2008, The Prostate.

[2]  Francesco Porpiglia,et al.  Human ASH1 expression in prostate cancer with neuroendocrine differentiation , 2008, Modern Pathology.

[3]  R. Autorino,et al.  Neuroendocrine Immunophenotype as Predictor of Clinical Recurrence in 110 Patients with Prostate Cancer , 2007, International journal of immunopathology and pharmacology.

[4]  A. Scorilas,et al.  Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. , 2007, Anticancer research.

[5]  M. Papotti,et al.  Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. , 2007, The Journal of urology.

[6]  Toscano Vincenzo,et al.  Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. , 2007, Endocrine-related cancer.

[7]  G. Gatta,et al.  Regional Estimates of Prostate Cancer Burden in Italy , 2007, Tumori.

[8]  H. Frierson,et al.  Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. , 2007, Cancer research.

[9]  S. Gunia,et al.  Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy , 2007, Scandinavian journal of urology and nephrology.

[10]  Jiaoti Huang,et al.  Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer* , 2006, Journal of Biological Chemistry.

[11]  S. Batra,et al.  Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. , 2006, Endocrine-related cancer.

[12]  M. Cooperberg,et al.  The changing face of prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Kantoff,et al.  Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. , 2005, Urology.

[14]  C. Supuran,et al.  Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. , 2005, European urology.

[15]  L. Dogliotti,et al.  Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. , 2005, Endocrine-related cancer.

[16]  P. Abrahamsson,et al.  Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.

[17]  B. Conley,et al.  Detection of Prostate Cancer and Predicting Progression , 2004, Clinical Cancer Research.

[18]  S. Monti,et al.  Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma , 2003, The Prostate.

[19]  P. Scardino,et al.  National Comprehensive Cancer Network guidelines for the management of prostate cancer. , 2003, Urology.

[20]  D. Bostwick,et al.  Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. , 2002, The Journal of urology.

[21]  T. H. van der Kwast,et al.  Different profiles of neuroendocrine cell differentiation evolve in the PC‐310 human prostate cancer model during long‐term androgen deprivation , 2002, The Prostate.

[22]  J. Hugosson,et al.  Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. , 2000, Urology.

[23]  M W Kattan,et al.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[25]  P. di Sant'Agnese,et al.  Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma , 1998, The Prostate. Supplement.

[26]  H. Frierson,et al.  Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate , 1997, Cancer.

[27]  L. McWilliam,et al.  Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. , 1997, British journal of urology.

[28]  A. Partin,et al.  Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.

[29]  H. Moch,et al.  Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.

[30]  T. H. van der Kwast,et al.  The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long‐term follow‐up study with patients treated by radical prostatectomy , 1995, International journal of cancer.